CureDuchenne will host CureDuchenne Fuerza 2025, a one-day educational and community-building conference on October 25, 2025, in Mexico City. The event forms part of CureDuchenne’s international program and is presented in collaboration with advocacy, clinical, and research partners across Mexico.

The bilingual conference is free and open to individuals and families affected by Duchenne and Becker muscular dystrophy, healthcare professionals, government officials, advocates, and industry representatives. Attendees can join in person, virtually, or via local watch parties in other states across Mexico. Local transportation support is available for families attending in person, while virtual sessions will be offered free of charge to ensure broad access.

“Our mission is to improve care for individuals with Duchenne everywhere,” Debra Miller, founder and CEO of CureDuchenne, said: “Fuerza 2025 is not just a conference—it’s a movement of strength, knowledge, and community across borders.”

The conference aims to expand clinical knowledge for healthcare providers, engage key opinion leaders, improve standards of care in Mexico, and provide families with information on research and emerging therapies. Sessions will cover multi-disciplinary care including cardiac and respiratory management, physical therapy demonstrations, and updates on emerging treatments. Breakout sessions are designed for caregivers, individuals with Duchenne or Becker, and healthcare professionals, alongside advocacy and resource networking to connect families with local and national support systems.

The event reflects a growing focus on international collaboration in rare diseases, helping to strengthen local healthcare networks and ensure that individuals with Duchenne and Becker muscular dystrophy receive timely, evidence-based care. Families will also have the opportunity to engage with peer networks, share experiences, and access resources tailored to their needs.

Founded more than 20 years ago, CureDuchenne accelerates research and improves care for people with Duchenne muscular dystrophy. Its initiatives include clinical trial support, development of certified physical and occupational therapists, and a data-integrated biobank to advance research toward new treatments.